About Creative Biolabs
Founded in 2005, Creative Biolabs, part of the Creative group, specialises in antibody discovery, protein engineering and biologics development for life science research and therapeutic programmes. Its scientific expertise spans monoclonal antibodies, recombinant proteins, antibody-drug conjugates (ADCs), bispecific antibodies and cell-based immunotherapies. The company applies technologies including hybridoma development, phage display, antibody engineering and target validation platforms to support studies in oncology, immunology, infectious disease, autoimmune disorders and translational medicine. These capabilities enable researchers to identify, optimise and characterise therapeutic candidates while advancing target discovery and biomarker research.
Creative Biolabs offers an extensive portfolio of recombinant antibodies, engineered antibody formats, therapeutic proteins, immunotoxins, biomarker reagents and assay development services. Proprietary platforms include its Creative Discovery Platform™ for bispecific antibody development, alongside capabilities for ADC generation, antibody characterisation, cell-free expression and glycosylation analysis. Its products and services support workflows including immunoassay development, protein interaction studies, tumour marker detection, tissue imaging, functional assays and preclinical therapeutic research.
Europa Biosite’s subsidiaries distribute for Capsid Biotechnology in Ireland, Switzerland and the United Kingdom.